{"id":"flot","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"20-40","effect":"Mucositis"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"907ac4a4-a088-4826-ab50-cfc31985c9d4","title":"POSLUMA (FLOTUFOLASTAT F-18) INJECTION [BLUE EARTH DIAGNOSTICS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FLOT is a polychemotherapy combination where fluorouracil and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, oxaliplatin creates DNA cross-links, and docetaxel stabilizes microtubules to prevent cell division. This multi-agent approach targets cancer cells through complementary mechanisms of action, commonly used in gastric and gastroesophageal junction cancers.","oneSentence":"FLOT is a chemotherapy regimen combining fluorouracil, leucovorin, oxaliplatin, and docetaxel to inhibit DNA synthesis and microtubule formation, killing rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:00:16.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or locally advanced gastric cancer"},{"name":"Gastroesophageal junction adenocarcinoma"},{"name":"Perioperative treatment of resectable gastric cancer"}]},"trialDetails":[{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT05567835","phase":"PHASE2","title":"A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2024-03-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":3},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT07359443","phase":"PHASE1","title":"Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2025-05-21","conditions":"Esophageal Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Adenocarcinoma - Gastroesophageal Junction (GEJ)","enrollment":39},{"nctId":"NCT06967987","phase":"PHASE2","title":"Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b","status":"WITHDRAWN","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2026-01-01","conditions":"Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b","enrollment":""},{"nctId":"NCT07313579","phase":"","title":"Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","status":"RECRUITING","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2025-12-01","conditions":"Gastric Cancer (GC), HIPEC, Peritoneal Metastases From Gastric Cancer","enrollment":200},{"nctId":"NCT07059611","phase":"PHASE2","title":"Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-01","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":34},{"nctId":"NCT04028167","phase":"PHASE2","title":"Induction FLOT With CROSS CRT for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-04-08","conditions":"Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction","enrollment":40},{"nctId":"NCT07283848","phase":"PHASE2","title":"Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction","enrollment":""},{"nctId":"NCT04592913","phase":"PHASE3","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-17","conditions":"Gastrointestinal Neoplasms, Esophagogastric Junction","enrollment":957},{"nctId":"NCT06161818","phase":"PHASE2","title":"Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-09-12","conditions":"Esophageal Cancer, Adenocarcinoma of the Esophagus","enrollment":216},{"nctId":"NCT07059299","phase":"PHASE1","title":"A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-12-12","conditions":"Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":18},{"nctId":"NCT07101666","phase":"PHASE2","title":"Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-01-31","conditions":"Gastric Cancer","enrollment":20},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT05836584","phase":"PHASE2","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-06","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":240},{"nctId":"NCT06313801","phase":"PHASE2","title":"Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions","status":"RECRUITING","sponsor":"Nizhny Novgorod Regional Clinical Oncology Center","startDate":"2023-01-19","conditions":"Gastric Cancer","enrollment":106},{"nctId":"NCT07222657","phase":"PHASE2","title":"Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Esophageal Adenocarcinoma, Esophageal Cancer","enrollment":40},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT05709574","phase":"PHASE2","title":"Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-04-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":10},{"nctId":"NCT07018570","phase":"PHASE2","title":"An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2025-07-24","conditions":"Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":26},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT03421288","phase":"PHASE2","title":"Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-09-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":677},{"nctId":"NCT03636893","phase":"PHASE2","title":"Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-08-24","conditions":"Gastric Cancer, Chemotherapy Effect","enrollment":74},{"nctId":"NCT06906887","phase":"PHASE2","title":"PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-06-17","conditions":"Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer","enrollment":50},{"nctId":"NCT05504720","phase":"PHASE2","title":"Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-02-13","conditions":"Esophagogastric Adenocarcinoma","enrollment":31},{"nctId":"NCT06440811","phase":"","title":"Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2021-01-01","conditions":"Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":120},{"nctId":"NCT06978062","phase":"PHASE1","title":"Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-02-20","conditions":"GastroEsophageal Cancer","enrollment":27},{"nctId":"NCT06784765","phase":"NA","title":"Preventive Use of PIPAC in Locally Advanced Gastric Cancer.","status":"RECRUITING","sponsor":"National Research Oncology and Transplantology Center, Kazakhstan","startDate":"2025-01-15","conditions":"Gastric Cancer","enrollment":160},{"nctId":"NCT06028737","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2025-03-25","conditions":"Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer","enrollment":150},{"nctId":"NCT06933966","phase":"PHASE2","title":"Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-09-01","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Non Metastatic Disease","enrollment":120},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT05296005","phase":"PHASE1","title":"Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2025-12-31","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8","enrollment":""},{"nctId":"NCT04162665","phase":"PHASE2","title":"Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-02-14","conditions":"Gastric Adenocarcinoma","enrollment":4},{"nctId":"NCT04375605","phase":"PHASE3","title":"Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsmedizin Mannheim","startDate":"2020-06-03","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":342},{"nctId":"NCT04745988","phase":"PHASE2","title":"An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2021-11-11","conditions":"Gastric Cancer","enrollment":43},{"nctId":"NCT02578368","phase":"PHASE3","title":"Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2016-02","conditions":"Gastric Cancer","enrollment":183},{"nctId":"NCT04447352","phase":"PHASE3","title":"HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)","status":"RECRUITING","sponsor":"Krankenhaus Nordwest","startDate":"2020-12-17","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":200},{"nctId":"NCT06642506","phase":"","title":"Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2024-10-06","conditions":"Esophagus Adenocarcinoma, Esophagus Cancer, Metabolome","enrollment":20},{"nctId":"NCT06684158","phase":"PHASE2","title":"Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-30","conditions":"GC/GEJC","enrollment":70},{"nctId":"NCT06681298","phase":"PHASE2","title":"A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"xiaohua li","startDate":"2024-05-01","conditions":"Adenocarcinoma of the Esophagogastric Junction, Perioperative Period","enrollment":36},{"nctId":"NCT03979131","phase":"PHASE2","title":"Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2019-08-22","conditions":"Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms","enrollment":40},{"nctId":"NCT04937738","phase":"PHASE2","title":"Perioperative Chemotherapy in Gastric Cancer","status":"TERMINATED","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":69},{"nctId":"NCT06459921","phase":"PHASE2","title":"Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-12-01","conditions":"Neoadjuvant Chemotherapy, Sintilimab, Locally Advanced Gastric Cancer","enrollment":200},{"nctId":"NCT05713838","phase":"PHASE2","title":"Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-08-28","conditions":"Esophagus Adenocarcinoma","enrollment":32},{"nctId":"NCT05715931","phase":"PHASE2","title":"Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Yu jiren","startDate":"2023-02-28","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer","enrollment":30},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT03647969","phase":"PHASE2","title":"Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-11-07","conditions":"Adenocarcinoma of the Stomach, GastroEsophageal Cancer","enrollment":262},{"nctId":"NCT06253650","phase":"PHASE2","title":"Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-01","conditions":"Gastric Cancer, HER2-positive Gastric Cancer","enrollment":46},{"nctId":"NCT04891016","phase":"PHASE2","title":"Toripalimab Plus FLOT in Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-06-25","conditions":"Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma","enrollment":60},{"nctId":"NCT06411171","phase":"PHASE3","title":"Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:","status":"NOT_YET_RECRUITING","sponsor":"xiaohua li","startDate":"2024-06-01","conditions":"Gastroesophageal Junction Cancer","enrollment":36},{"nctId":"NCT04878783","phase":"","title":"Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Roma La Sapienza","startDate":"2019-12-20","conditions":"Gastric Cancer, Adenocarcinoma of the Stomach","enrollment":138},{"nctId":"NCT02509286","phase":"PHASE3","title":"Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2016-01","conditions":"Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction","enrollment":438},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT04062656","phase":"PHASE2","title":"Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG","status":"UNKNOWN","sponsor":"University Hospital, Essen","startDate":"2019-09-26","conditions":"Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction","enrollment":21},{"nctId":"NCT04597294","phase":"PHASE3","title":"Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2021-08-01","conditions":"Gastric Cancer","enrollment":600},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT05960955","phase":"PHASE2","title":"Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-11-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT05264896","phase":"PHASE3","title":"Perioperative FLOT vs Adjuvant XELOX for CA Stomach","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-03-21","conditions":"Cancer of Stomach, Adenocarcinoma","enrollment":110},{"nctId":"NCT05982301","phase":"PHASE2","title":"Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-02-09","conditions":"Gastric Cancer, Chemotherapy Effect, Immune Checkpoint Inhibitor","enrollment":87},{"nctId":"NCT03399071","phase":"PHASE2","title":"Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-07-31","conditions":"Gastric Adenocarcinoma, Oesophageal Adenocarcinoma","enrollment":44},{"nctId":"NCT05620524","phase":"","title":"Therapeutic Oncolytic Monitoring as a Tool for Effective Exposure to 5-FU in Patients With Locally Advanced, Resectable Gastric or Gastro-oesophageal Junction Cancer Treated With Perioperative FLOT","status":"UNKNOWN","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2022-12-19","conditions":"TDM of 5-FU, Pharmacokinetic Observational Study","enrollment":20},{"nctId":"NCT04736485","phase":"PHASE2","title":"Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2021-06-28","conditions":"Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma","enrollment":67},{"nctId":"NCT05610332","phase":"PHASE3","title":"Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2022-11-01","conditions":"Locally Advanced Gastric Cancer","enrollment":216},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT04699994","phase":"PHASE2","title":"Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel","status":"UNKNOWN","sponsor":"Keio University","startDate":"2020-06-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT05466019","phase":"PHASE2","title":"A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2021-05-01","conditions":"PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer","enrollment":30},{"nctId":"NCT02661971","phase":"PHASE2, PHASE3","title":"FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2016-06","conditions":"Stomach Cancer, Gastroesophageal Junction Cancer","enrollment":180},{"nctId":"NCT05054322","phase":"PHASE2, PHASE3","title":"FLuticasone in cOvid Treatment (FLOT)","status":"UNKNOWN","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2021-09-22","conditions":"Covid19","enrollment":500},{"nctId":"NCT04341857","phase":"PHASE2","title":"PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-07-30","conditions":"Gastric and Esophagogastric Junction Adenocarcinoma","enrollment":25},{"nctId":"NCT04384601","phase":"PHASE3","title":"Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2021-09","conditions":"Gastric Cancer, Neoadjuvant Chemotherapy","enrollment":246},{"nctId":"NCT04886193","phase":"NA","title":"FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2021-04-16","conditions":"Chemotherapy, Gastric Cancer","enrollment":20},{"nctId":"NCT04393584","phase":"PHASE2, PHASE3","title":"FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2019-01-29","conditions":"Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel","enrollment":538},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT04354662","phase":"PHASE2","title":"Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-09-26","conditions":"Gastric Cancer","enrollment":35},{"nctId":"NCT04595929","phase":"NA","title":"Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-02-10","conditions":"Peritoneal Carcinomatosis, Gastric Cancer","enrollment":304},{"nctId":"NCT03646591","phase":"","title":"Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2017-11-15","conditions":"Chemotherapy Effect","enrollment":10},{"nctId":"NCT02581462","phase":"PHASE2, PHASE3","title":"FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2016-06","conditions":"Stomach Cancer, Gastroesophageal Junction Cancer","enrollment":81},{"nctId":"NCT03606928","phase":"PHASE1, PHASE2","title":"mFLOT Chemotherapy as First-line Treatment in GC","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-07-01","conditions":"Gastric Cancer","enrollment":18},{"nctId":"NCT03961841","phase":"PHASE3","title":"Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-06","conditions":"Esophagogastric Junction Disorder, Neoplasms","enrollment":900},{"nctId":"NCT01216644","phase":"PHASE2, PHASE3","title":"5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2010-08","conditions":"Gastric Cancer","enrollment":716},{"nctId":"NCT03451942","phase":"PHASE2","title":"The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-02-05","conditions":"Adenocarcinoma of the Stomach / Gastroesophageal","enrollment":112},{"nctId":"NCT01504256","phase":"PHASE2","title":"Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2011-10","conditions":"Gastric Adenocarcinoma With Peritoneal Carcinomatosis, Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis, Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis","enrollment":42},{"nctId":"NCT01472029","phase":"PHASE2","title":"Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2011-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach","enrollment":53},{"nctId":"NCT00849615","phase":"PHASE2","title":"Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2009-02","conditions":"Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction","enrollment":252},{"nctId":"NCT01932580","phase":"PHASE2","title":"Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"McGill University","startDate":"2013-08","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":10},{"nctId":"NCT00737373","phase":"PHASE2","title":"Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2007-08","conditions":"Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction","enrollment":143},{"nctId":"NCT01160419","phase":"PHASE2","title":"Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2009-12","conditions":"Gastric Cancer","enrollment":49},{"nctId":"NCT01206218","phase":"PHASE2, PHASE3","title":"Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2010-10","conditions":"Advanced Gastric Cancer","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":449,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FLOT","genericName":"FLOT","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FLOT is a chemotherapy regimen combining fluorouracil, leucovorin, oxaliplatin, and docetaxel to inhibit DNA synthesis and microtubule formation, killing rapidly dividing cancer cells. Used for Metastatic or locally advanced gastric cancer, Gastroesophageal junction adenocarcinoma, Perioperative treatment of resectable gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}